The Sohn Conference Foundation pursues preeminent and bold initiatives that will have the greatest impact to treat and cure pediatric cancer. However, given 2020’s global pandemic, this year’s proceeds will support research to fight the COVID-19 virus.
All proceeds from the 2020 Healthcare-Focused Sohn Investment Conference will support Rockefeller University’s Dr. Michel Nussenzweig, who is developing a novel therapy for COVID-19. Dr. Nussenzweig’s potent monoclonal antibodies against SARS-CoV-2 will enter clinical trials this fall. He is using an approach he pioneered several years ago discovering and harnessing neutralizing antibodies against HIV. Gilead Sciences recently acquired the license to develop this new HIV antibody therapy. The Nussenzweig lab continues to spearhead the design of effective therapies against other known and emerging global infectious diseases.
Founded in 1901 to improve the understanding of life for the benefit of humanity, Rockefeller is one of the world’s leading biomedical research institutions. Rockefeller scientists have garnered 25 Nobel Prizes in Chemistry or Medicine, a number that would rank the institution as fourth in the world if it was its own country. We’re excited to come together to support Rockefeller’s culture of excellence, which is unrivaled among research institutions worldwide.